Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01
STOCKHOLM, SWEDEN February 25, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has dosed…
